208
Views
5
CrossRef citations to date
0
Altmetric
Letters to the Editor

Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 1752-1755 | Received 07 Dec 2019, Accepted 22 Feb 2020, Published online: 11 Mar 2020
 

Author contributions

S.D. wrote the first draft and approved the final version of the manuscript; M.A.G., A.D., S.K.K., and S.A.P. revised the manuscript critically and approved the final version of the manuscript. E.D. mentored the manuscript writing and approved the final version of the manuscript.

Disclosure statement

Shweta Deshpande: None; Morie A. Gertz: Consultancy (Millenium) and honoraria (Celgene, Millenium, Onyx, Novartis, Smith Kline, Prothena, Ionis). Angela Dispenzieri: Research funding (Celgene, Millennium, Pfizer, and Janssen), Travel grant (Pfizer). Shaji Kumar: Consultancy (Celgene, Millennium, Onyx, Janssen, and BMS); and research funding (Celgene, Millennium, Novartis, Onyx AbbVie, Janssen, and BMS). Sameer A. Parikh: Research funding has been provided to the institution from Pharmacyclics, MorphoSys, Janssen, AstraZeneca, TG Therapeutics, and Ascentage Pharma for clinical studies in which Sameer A.Parikh is a principal investigator. Sameer A.Parikh has also participated in Advisory Board meetings of Pharmacyclics, AstraZeneca, Genentech, Gilead, and AbbVie (he was not personally compensated for his participation). Eli Muchtar: None.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.